Key facts
- This page summarizes COONEY CHARLES L's Form 4 filing for GreenLight Biosciences Holdings, PBC.
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 26 Jul 2023, 21:28.
COONEY CHARLES L - 24 Jul 2023 Form 4 Insider Report for GreenLight Biosciences Holdings, PBC
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 24 Jul 2023
- Net transaction value
- -$91,594
- SEC form
- 4
- Accepted by SEC
- 26 Jul 2023, 21:28:33 UTC
- Prior SEC filing
- 21 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Charles Cooney
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
COONEY CHARLES L filed Form 4 for GreenLight Biosciences Holdings, PBC on 26 Jul 2023.
Change
- Previous filing in this sequence was filed on 21 Feb 2023.
- Current net transaction value: -$91,594.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GRNA
transaction
Common Stock
Disposition pursuant to a tender of shares in a change of control transaction
- Transaction value
- $91,594
- Shares
- -305,314
- Change %
- -100%
- Price
- $0.3000
- Shares after
- 0
- Date
- 24 Jul 2023
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
COONEY CHARLES L is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 29, 2023, by and among GreenLight Biosciences Holdings, PBC ("Issuer"), SW ParentCo, Inc. ("Parent"), and SW MergerCo, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), to which Merger Sub completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer effective as of July 24, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $0.30 per Share, in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.